Solid Tumor Cancer Clinical Trial
The purpose of this study is to determine the expression of molecules involved in the glycine/serine pathway using immunohistochemistry in solid tumors. Archived paraffin-embedded pathological specimens from the Department of Pathology, NUH will be obtained. Tissue microarray (TMA) is a high-throughput method of analysing large numbers of formalin-fixed, paraffin-embedded tumor at a minimal cost and effort. To analyse the expression of molecules of putative relevance to the glycine/serine pathway, (such as PSPH, PSAT1, SHMT1, and GLDC), TMA technology will be utilised as previously reported (Kristiansen, Zhang, Soong). Tissue arrays will be constructed from solid tumors including cancers of the colon/ rectum, lung, breast, cervix, ovary, endometrium, fallopian tube, prostate, kidney, testis, stomach, liver, brain and lymphoma. One hundred cases of each tumor type (subject to availability) will be stained using immunohistochemistry. Patient Identifiers will not be collected. Societal benefit in terms of knowledge gained to improve understanding of cancer. No direct risk to subjects as this is a retrospective study of archived pathological tumour samples.
n/a
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00891761 -
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
|
Phase 3 | |
| Completed |
NCT00046111 -
A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00119171 -
Ispinesib In Combination With Capecitabine In Patients With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04354064 -
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
|
||
| Completed |
NCT00169520 -
SB-715992 In Combination With Docetaxel In Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT00085878 -
Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors
|
Phase 1 | |
| Completed |
NCT00136513 -
SB-743921 In Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT00085904 -
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
|
Phase 1 | |
| Completed |
NCT06042400 -
Trial of Written Exposure for Metastatic Cancer Patients (EASE)
|
N/A |